Skip to main content
Erschienen in: Die Kardiologie 2/2020

19.03.2020 | Kardiomyopathie | CME

Kardiale Amyloidose

verfasst von: D. Frumkin, K. Hahn, F. Kleefeld, K. Nogai, C. Wetz, D. Messroghli, Prof. Dr. F. Knebel

Erschienen in: Die Kardiologie | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Amyloidosen sind eine heterogene Gruppe von Proteinspeichererkrankungen, die mit chronisch entzündlichen Erkrankungen und monoklonalen Gammopathien assoziiert sind oder als familiäre Erkrankung auftreten. Allen zugrunde liegt eine Ablagerung löslicher Serumproteine im Extrazellulärraum von Organen, Gefäßen und Nerven. Je nach Subtyp ist eine kardiale Mitbeteiligung häufig und führend für die hohe Mortalität der Erkrankung verantwortlich. Die Mehrzahl der Amyloidosen ist heute effektiv behandelbar, sofern sie frühzeitig erkannt und differenziert wird. Dazu steht eine Vielzahl gut validierter invasiver als auch nichtinvasiver diagnostischer Mittel zur Verfügung. Für eine optimale Versorgung der Patienten muss die klinische Symptomatik der Amyloidose in ihren Variationen bekannt sein, und es müssen rasch die richtigen diagnostischen und therapeutischen Schritte erfolgen. Da die heute zur Verfügung stehenden Therapieformen sehr spezifisch sind, sollten Patienten an ein Zentrum mit spezieller Expertise und der Möglichkeit einer interdisziplinären Betreuung überwiesen werden.
Literatur
1.
Zurück zum Zitat Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349(6):583–596PubMed Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349(6):583–596PubMed
2.
Zurück zum Zitat Yilmaz A, Bauersachs J, Kindermann I et al (2019) Diagnostics and treatment of cardiac amyloidosis Position paper of the German Cardiac Society (DGK). Kardiologe 13:264 Yilmaz A, Bauersachs J, Kindermann I et al (2019) Diagnostics and treatment of cardiac amyloidosis Position paper of the German Cardiac Society (DGK). Kardiologe 13:264
3.
Zurück zum Zitat Damy T, Costes B, Hagege AA, Donal E, Eicher JC, Slama M et al (2016) Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J 37(23):1826–1834PubMed Damy T, Costes B, Hagege AA, Donal E, Eicher JC, Slama M et al (2016) Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J 37(23):1826–1834PubMed
4.
Zurück zum Zitat Vaxman I, Gertz M (2019) Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis. Acta Haematol 141(2):93–106PubMed Vaxman I, Gertz M (2019) Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis. Acta Haematol 141(2):93–106PubMed
5.
Zurück zum Zitat Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O’Fallon WM et al (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79(7):1817–1822PubMed Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O’Fallon WM et al (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79(7):1817–1822PubMed
6.
Zurück zum Zitat Cornwell GG 3rd, Murdoch WL, Kyle RA, Westermark P, Pitkanen P (1983) Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 75(4):618–623PubMed Cornwell GG 3rd, Murdoch WL, Kyle RA, Westermark P, Pitkanen P (1983) Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 75(4):618–623PubMed
7.
Zurück zum Zitat Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM et al (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2(2):113–122PubMedPubMedCentral Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM et al (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2(2):113–122PubMedPubMedCentral
8.
Zurück zum Zitat Cavalcante JL, Rijal S, Abdelkarim I, Althouse AD, Sharbaugh MS, Fridman Y et al (2017) Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson 19(1):98PubMedPubMedCentral Cavalcante JL, Rijal S, Abdelkarim I, Althouse AD, Sharbaugh MS, Fridman Y et al (2017) Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson 19(1):98PubMedPubMedCentral
9.
Zurück zum Zitat Koivuniemi R, Paimela L, Suomalainen R, Tornroth T, Leirisalo-Repo M (2008) Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 15(4):262–268PubMed Koivuniemi R, Paimela L, Suomalainen R, Tornroth T, Leirisalo-Repo M (2008) Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 15(4):262–268PubMed
10.
Zurück zum Zitat Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G (2015) Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther 32(10):920–928PubMedPubMedCentral Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G (2015) Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther 32(10):920–928PubMedPubMedCentral
11.
Zurück zum Zitat Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW et al (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116(21):2420–2426PubMed Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW et al (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116(21):2420–2426PubMed
12.
Zurück zum Zitat Dorbala S, Vangala D, Bruyere J Jr., Quarta C, Kruger J, Padera R et al (2014) Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail 2(4):358–367PubMedPubMedCentral Dorbala S, Vangala D, Bruyere J Jr., Quarta C, Kruger J, Padera R et al (2014) Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail 2(4):358–367PubMedPubMedCentral
13.
Zurück zum Zitat Wajnsztajn F, Kim A, Boehme A, Maurer M, Brannagan T (2018) Peripheral neuropathy in wild type transthyretin amyloidosis. (P1.438). Neurology 90(15 Supplement):P1.438 Wajnsztajn F, Kim A, Boehme A, Maurer M, Brannagan T (2018) Peripheral neuropathy in wild type transthyretin amyloidosis. (P1.438). Neurology 90(15 Supplement):P1.438
14.
Zurück zum Zitat Hahn K, Urban P, Meliss RR, Axmann HD, Siebert F, Rocken C (2018) Carpal tunnel syndrome and ATTR-amyloidosis. Handchir Mikrochir Plast Chir 50(5):329–334PubMed Hahn K, Urban P, Meliss RR, Axmann HD, Siebert F, Rocken C (2018) Carpal tunnel syndrome and ATTR-amyloidosis. Handchir Mikrochir Plast Chir 50(5):329–334PubMed
15.
Zurück zum Zitat Matsuda M, Gono T, Morita H, Katoh N, Kodaira M, Ikeda S (2011) Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study. Eur J Neurol 18(4):604–610PubMed Matsuda M, Gono T, Morita H, Katoh N, Kodaira M, Ikeda S (2011) Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study. Eur J Neurol 18(4):604–610PubMed
16.
Zurück zum Zitat Ando Y, Suhr OB (1998) Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid 5(4):288–300PubMed Ando Y, Suhr OB (1998) Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid 5(4):288–300PubMed
17.
Zurück zum Zitat Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O et al (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120(13):1203–1212PubMed Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O et al (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120(13):1203–1212PubMed
18.
Zurück zum Zitat Nativi-Nicolau J, Maurer MS (2018) Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol 33(5):571–579PubMed Nativi-Nicolau J, Maurer MS (2018) Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol 33(5):571–579PubMed
19.
Zurück zum Zitat Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M et al (2010) Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 7(7):398–408PubMed Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M et al (2010) Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 7(7):398–408PubMed
20.
Zurück zum Zitat Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F et al (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34(7):520–528PubMed Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F et al (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34(7):520–528PubMed
21.
Zurück zum Zitat Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B et al (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid outcome survey). J Am Coll Cardiol 68(2):161–172PubMedPubMedCentral Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B et al (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid outcome survey). J Am Coll Cardiol 68(2):161–172PubMedPubMedCentral
22.
Zurück zum Zitat Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD et al (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356(23):2361–2371PubMed Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD et al (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356(23):2361–2371PubMed
23.
Zurück zum Zitat Frumkin D, Taube ET, Stangl K, Knebel F (2019) Rapid progression of aortic and mitral stenosis in a patient with AA amyloidosis: a case report. Eur Heart J Case Rep 3(2):2514–2119 Frumkin D, Taube ET, Stangl K, Knebel F (2019) Rapid progression of aortic and mitral stenosis in a patient with AA amyloidosis: a case report. Eur Heart J Case Rep 3(2):2514–2119
24.
Zurück zum Zitat Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD et al (2002) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 346(23):1786–1791PubMed Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD et al (2002) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 346(23):1786–1791PubMed
25.
Zurück zum Zitat Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30(9):989–995PubMedPubMedCentral Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30(9):989–995PubMedPubMedCentral
26.
Zurück zum Zitat Sperry BW, Vranian MN, Hachamovitch R, Joshi H, McCarthy M, Ikram A et al (2016) Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol 214:477–481PubMed Sperry BW, Vranian MN, Hachamovitch R, Joshi H, McCarthy M, Ikram A et al (2016) Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol 214:477–481PubMed
27.
Zurück zum Zitat Namdar M, Steffel J, Jetzer S, Schmied C, Hurlimann D, Camici GG et al (2012) Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease. Am J Cardiol 109(4):587–593PubMed Namdar M, Steffel J, Jetzer S, Schmied C, Hurlimann D, Camici GG et al (2012) Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease. Am J Cardiol 109(4):587–593PubMed
28.
Zurück zum Zitat Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16(3):233–270PubMed Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16(3):233–270PubMed
29.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200PubMed Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200PubMed
30.
Zurück zum Zitat Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC et al (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98(19):1442–1448PubMed Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC et al (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98(19):1442–1448PubMed
31.
Zurück zum Zitat Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J et al (2017) Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging 10(3):e5588PubMed Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J et al (2017) Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging 10(3):e5588PubMed
32.
Zurück zum Zitat Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL et al (2017) Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular Imaging (EACVI) 2017. Eur Heart J Cardiovasc Imaging 18(11):1205PubMed Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL et al (2017) Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular Imaging (EACVI) 2017. Eur Heart J Cardiovasc Imaging 18(11):1205PubMed
33.
Zurück zum Zitat El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO et al (2019) Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol 73(5):589–597PubMedPubMedCentral El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO et al (2019) Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol 73(5):589–597PubMedPubMedCentral
34.
Zurück zum Zitat Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK et al (2014) Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 7(2):157–165PubMed Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK et al (2014) Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 7(2):157–165PubMed
35.
Zurück zum Zitat Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ (2008) Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 10:54PubMedPubMedCentral Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ (2008) Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 10:54PubMedPubMedCentral
36.
Zurück zum Zitat Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C et al (2019) Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging 12(5):810–819PubMed Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C et al (2019) Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging 12(5):810–819PubMed
37.
Zurück zum Zitat Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 19(1):75PubMedPubMedCentral Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 19(1):75PubMedPubMedCentral
38.
Zurück zum Zitat Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L et al (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc‑3,3‑diphosphono‑1,2‑propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46(6):1076–1084PubMed Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L et al (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc‑3,3‑diphosphono‑1,2‑propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46(6):1076–1084PubMed
39.
Zurück zum Zitat Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS (2013) (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 6(2):195–201PubMedPubMedCentral Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS (2013) (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 6(2):195–201PubMedPubMedCentral
41.
Zurück zum Zitat Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A et al (2010) Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 122(9):900–909PubMed Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A et al (2010) Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 122(9):900–909PubMed
42.
Zurück zum Zitat Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C (2017) Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135(14):1357–1377PubMedPubMedCentral Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C (2017) Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135(14):1357–1377PubMedPubMedCentral
43.
Zurück zum Zitat Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24):2404–2412PubMed Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133(24):2404–2412PubMed
44.
Zurück zum Zitat Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73(22):2872–2891PubMedPubMedCentral Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73(22):2872–2891PubMedPubMedCentral
45.
Zurück zum Zitat Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM et al (2011) Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 118(16):4346–4352PubMedPubMedCentral Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM et al (2011) Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 118(16):4346–4352PubMedPubMedCentral
46.
Zurück zum Zitat Schonland SO, Dreger P, de Witte T, Hegenbart U (2012) Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplant 47(7):895–905PubMed Schonland SO, Dreger P, de Witte T, Hegenbart U (2012) Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplant 47(7):895–905PubMed
47.
Zurück zum Zitat Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH et al (2012) Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 119(19):4387–4390PubMed Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH et al (2012) Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 119(19):4387–4390PubMed
48.
Zurück zum Zitat Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J et al (2007) Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 7(1):235–242PubMed Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J et al (2007) Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 7(1):235–242PubMed
49.
Zurück zum Zitat Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR et al (2015) Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99(9):1847–1854PubMed Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR et al (2015) Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99(9):1847–1854PubMed
50.
Zurück zum Zitat Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806–811PubMed Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806–811PubMed
51.
Zurück zum Zitat Buxbaum JN (2018) Oligonucleotide drugs for transthyretin amyloidosis. N Engl J Med 379(1):82–85PubMed Buxbaum JN (2018) Oligonucleotide drugs for transthyretin amyloidosis. N Engl J Med 379(1):82–85PubMed
52.
Zurück zum Zitat Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11–21PubMed Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11–21PubMed
53.
Zurück zum Zitat Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS et al (2019) Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139(4):431–443PubMed Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS et al (2019) Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139(4):431–443PubMed
54.
Zurück zum Zitat Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22–31PubMed Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22–31PubMed
55.
Zurück zum Zitat Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA et al (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A 109(24):9629–9634PubMedPubMedCentral Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA et al (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A 109(24):9629–9634PubMedPubMedCentral
56.
Zurück zum Zitat Coelho T, Maia LF, Martins da Silva A, Waddington CM, Plante-Bordeneuve V, Lozeron P et al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79(8):785–792PubMedPubMedCentral Coelho T, Maia LF, Martins da Silva A, Waddington CM, Plante-Bordeneuve V, Lozeron P et al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79(8):785–792PubMedPubMedCentral
Metadaten
Titel
Kardiale Amyloidose
verfasst von
D. Frumkin
K. Hahn
F. Kleefeld
K. Nogai
C. Wetz
D. Messroghli
Prof. Dr. F. Knebel
Publikationsdatum
19.03.2020
Verlag
Springer Medizin
Erschienen in
Die Kardiologie / Ausgabe 2/2020
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI
https://doi.org/10.1007/s12181-020-00382-4

Weitere Artikel der Ausgabe 2/2020

Die Kardiologie 2/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.